Discontinuation of Scheduled Infliximab in Crohn’s Patients With Clinical Remission: A Retrospective Single-Center Study

BACKGROUND: It is crucial to determine whether infliximab (IFX) therapy could be safely interrupted in Crohn’s disease (CD) patients with clinical remission. The outcome and risk predictors of relapse after IFX therapy stopped are controversial. The aim was to assess the relapse and predictive facto...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Huiqin, Xiang, Cheng, Qiu, Chen, Chen, Zhao, Huang, Silin, Liang, Li, Wang, Xinying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412541/
https://www.ncbi.nlm.nih.gov/pubmed/28496529
http://dx.doi.org/10.14740/gr800w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412541/
https://www.ncbi.nlm.nih.gov/pubmed/28496529
http://dx.doi.org/10.14740/gr800w

Ejemplares similares